Cisplatin Based Regimen for Advanced Pancreatic Cancer Patients with Homologous Recombination Deficiency

What this Trial Is About

This research aims to assess how well a cisplatin-based chemotherapy regimen works for patients with advanced pancreatic cancer who have homologous recombination deficiency (HRD). This subgroup of patients has specific genetic changes that may make them respond differently to treatments. The study focuses on those whose cancer has progressed after at least one prior chemotherapy and evaluates whether cisplatin can improve progression-free survival and other important outcomes. Participants will receive cisplatin at a dose of 25 mg/m2 through a 30-minute intravenous infusion on days 1 and 8 of each 21-day cycle. Other chemotherapy drugs may be given following standard guidelines depending on individual cases. Patients whose cancer is sensitive to platinum treatment may be offered a PARP inhibitor after six months of cisplatin therapy. Treatment cycles and response will be closely monitored throughout the study. During the trial, participants will be regularly assessed every four weeks for disease progression, tumor response, overall survival, and disease control using standard criteria. Researchers will conduct laboratory tests to ensure organ function and monitor safety. The study lasts until disease progression or other stopping criteria are met, with ongoing evaluations of treatment effects and participant well-being.

Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency